<DOC>
	<DOCNO>NCT02251652</DOCNO>
	<brief_summary>Sequential therapy cryosurgery ingenol mebutate may optimize treatment hypertrophic AKs also treat non-hypertrophic AKs anatomic location . Furthermore , use ingenol mebutate also evaluate potential treatment subclinical lesion .</brief_summary>
	<brief_title>Safety Efficacy Ingenol Mebutate 0.05 % Gel When Used After Cryotherapy Hypertrophic Actinic Keratoses</brief_title>
	<detailed_description>The investigator plan treat 30 subject . Each qualify subject least 3 hypertrophic AKs , define 3mm thickness , dorsal hand . Cryotherapy standardize patient treated lesion : 1-2 spray , 5 second , 5 second interval . All subject treat cryo-spray . Following cryotherapy , subject randomize treat either right leave dorsal hand ingenol mebutate gel . The decision treat right vs. leave hand choose chance , like flip coin . Neither subject study doctor choose arm receives ingenol mebutate gel . The study doctor know arm treat ingenol mebutate , subject reveal information time study . Subjects treat randomize dorsal hand ingenol mebutate 0.05 % gel start day cryotherapy ( Day 0 ) . Subjects utilize daily two day regimen . Subjects follow day 4 initial visit , day 8 , day 15 , day 29 , day 57 , two day window period .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<criteria>Adults least 18 year old . Subjects must good general health confirm medical history . Subjects must able read , sign , understand informed consent Prior cryosurgery , subject least 3 hypertrophic actinic keratoses dorsal hand . Subject must willing forego treatment dorsum hand , include tan bed use excessive sun exposure study . Subject willing able participate study outpatient , make frequent visit study center treatment followup period comply study requirement include concomitant medication treatment restriction . If subject female childbearing potential must negative urine pregnancy test result prior study treatment initiation must agree use approve method birth control enrol study . Subjects history melanoma anywhere body . Subjects unstable medical condition deem clinical investigator . Subjects nonmelanoma skin cancer dorsum hand . Subjects dermatologic disease treatment area may exacerbate treatment propose might impair evaluation AKs . Subjects previously treat ingenol mebutate : dorsum hand past 6 month ; outside study area within past 30 day . Women pregnant , lactating , plan become pregnant study period . Subjects experience clinically important medical event within 90 day visit ( e.g. , stroke , myocardial infarction , etc ) . Subjects active chemical dependency alcoholism assess investigator . Subjects know allergy excipient study gel . Subjects currently participate another clinical study complete another clinical study investigational drug device study area within 30 day prior study treatment initiation . Subjects receive follow within 90 day prior study treatment initiation : interferon interferon inducer cytotoxic drug immunomodulators immunosuppressive therapy ( inhaled/ intranasal steroid permit ) oral parenteral corticosteroid topical corticosteroid great 2 gm/day dermatologic procedure surgery study area ( include AK treatment ) Subjects use topical prescription medication study area within 30 day prior study treatment initiation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Actinic</keyword>
</DOC>